Analyst Price Target is $8.00
▲ +321.05% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Mersana Therapeutics in the last 3 months. The average price target is $8.00, with a high forecast of $14.00 and a low forecast of $2.00. The average price target represents a 321.05% upside from the last price of $1.90.
Current Consensus is
The current consensus among 7 investment analysts is to reduce stock in Mersana Therapeutics. This Reduce consensus rating has held steady for over two years.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.